Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer

Biomaterials

Volumn 30, Issue 15, 2009, Pages 2912-2918

  Chen, Chuang ^a,b   Peng, Jun ^c   Xia, He Shun ^d   Yang, Gui Fang ^c   Wu, Qiong Shui ^c   Chen, Liang Dong ^a,b   Zeng, Li Bo ^c   Zhang, Zhi Ling ^c   Pang, Dai Wen ^c   Li, Yan ^a,b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center   (China)

^c WUHAN UNIVERSITY   (China)

^d HUBEI CANCER HOSPITAL   (China)

Author keywords

Breast cancer; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Quantum dots

Indexed keywords

BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; HER2; IMMUNOHISTOCHEMISTRY; QUANTUM DOTS;

DIAGNOSIS; FLUORESCENCE; FLUORESCENCE MICROSCOPY; IMAGE ACQUISITION; PROBES;

SEMICONDUCTOR QUANTUM DOTS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; QUANTUM DOT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE PROBE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTUM DOT BASED IMMUNOFLUORESCENCE TECHNOLOGY; ROC CURVE;

BREAST NEOPLASMS; FEASIBILITY STUDIES; FLUORESCENT ANTIBODY TECHNIQUE; GENES, ERBB-2; HUMANS; QUANTUM DOTS; SENSITIVITY AND SPECIFICITY;

EID: 62549114852     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.02.010     Document Type: Article

References (39)

1. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 14 (2006) 2137-2150
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 1 (2007) 43-66
3. Yang L., Li L.D., Chen Y.D., and Parkin D.M. Time trends, estimates and projects for breast cancer incidence and mortality in China. Chin J Oncol 28 6 (2006) 438-440
4. Wang Q.J., Zhu W.X., and Xing X.M. Analysis of the incidence and survival of female breast cancer in Beijing during the last 20 years. Chin J Oncol 28 3 (2006) 208-210
5. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357 1 (2007) 39-51
6. Liberato N.L., Marchetti M., and Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25 6 (2007) 625-633
7. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
8. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 1 (2007) 118-145
9. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 10 (2005) 1569-1583
10. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26 45 (2007) 6469-6487
11. Tsuda H. HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer 13 3 (2006) 236-248
12. Group of guideline of HER2 detection in breast cancer. Guideline of HER2 detection in breast cancer. Chin J Pathol 35 10 (2006) 631-633
13. Payne S.J., Bowen R.L., Jones J.L., and Wells C.A. Predictive markers in breast cancer-the present. Histopathology 52 1 (2008) 82-90
14. Ginestier C., Charafe-Jauffret E., Penault-Llorca F., Geneix J., Adelaide J., Chaffanet M., et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 202 3 (2004) 286-298
15. Taylor C.R., and Levenson R.M. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 49 4 (2006) 411-424
16. Yaziji H., Goldstein L.C., Barry T.S., Werling R., Hwang H., Ellis G.K., et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 16 (2004) 1972-1977
17. Hyun C.L., Lee H.E., Kim K.S., Kim S.W., Kim J.H., Choe G., et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 61 3 (2008) 317-321
18. Vanden Bempt I., Drijkoningen M., and De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 19 6 (2007) 552-557
19. Yu X., Chen L., Deng Y., Li K., Wang Q., Li Y., et al. Fluorescence analysis with quantum dot probes for hepatoma under one- and two-photon excitation. J Fluoresc 17 2 (2007) 243-247
20. Chen C., Chen L.D., Zhang Z.L., and Li Y. Advances in the application of quantum dots in tumor markers investigation. Chin Ger J Clin Oncol 7 3 (2008) 179-184
21. Chen L.D., Liu J., Yu X.F., He M., Pei X.F., Tang Z.Y., et al. The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials 29 31 (2008) 4170-4176
22. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 114 2 (2006) 165-172
23. Xing Y., Chaudry Q., Shen C., Kong K.Y., Zhau H.E., Chung L.W., et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2 5 (2007) 1152-1165
24. True L.D., and Gao X. Quantum dots for molecular pathology: their time has arrived. J Mol Diagn 9 1 (2007) 7-11
25. Wu X., Liu H., Liu J., Haley K.N., Treadway J.A., Larson J.P., et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21 1 (2003) 41-46
26. Resch-Genger U., Grabolle M., Cavaliere-Jaricot S., Nitschke R., and Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat Methods 5 9 (2008) 763-775
27. Tholouli E., Sweeney E., Barrow E., Clay V., Hoyland J., and Byers R. Quantum dots light up pathology. J Pathol 216 3 (2008) 275-285
28. Yezhelyev M.V., Al-Hajj A., Morris C., Marcus A.I., Liu T., Lewis M., et al. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv Mater 19 20 (2007) 3146-3151
29. Tada H., Higuchi H., Wanatabe T.M., and Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 67 3 (2007) 1138-1144
30. Xiao Y., Gao X., Gannot G., Emmert-Buck M.R., Srivastava S., Wagner P.D., et al. Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int J Cancer 122 10 (2008) 2178-2186
31. Zeng X., Zhao D.C., Zhou W.X., Wu S.F., Liang Z.Y., and Liu T.H. Evaluation of HER2 gene expression status in breast cancer by fluorescence in situ hybridization. Chin J Pathol 34 11 (2005) 701-705
32. Hu Y., Wu Q., Liu S., Wei L., Chen X., Yan Z., et al. Study of rice pollen grains by multispectral imaging microscopy. Microsc Res Tech 68 6 (2005) 335-346
33. Guo N., Zeng L., and Wu Q. A method based on multispectral imaging technique for white blood cell segmentation. Comput Biol Med 37 1 (2007) 70-76
34. Dickinson M.E., Bearman G., Tille S., Lansford R., and Fraser S.E. Multi-spectral imaging and linear unmixing add a whole new dimension to laser scanning fluorescence microscopy. Biotechniques 31 6 (2001) 1272 1274-76, 1278
35. Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24 19 (2006) 3032-3038
36. Dowsett M., Hanna W.M., Kockx M., Penault-Llorca F., Ruschoff J., Gutjahr T., et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 20 5 (2007) 584-591
37. Owens M.A., Horten B.C., and Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5 1 (2004) 63-69
38. Press M.F., Sauter G., Bernstein L., Villalobos I.E., Mirlacher M., Zhou J.Y., et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11 18 (2005) 6598-6607
39. Zweig M.H., and Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39 4 (1993) 561-577